Bristows elects dual-qualified Xisca Borrás to the firm’s partnership, strengthening its life sciences regulatory practice

Xisca specialises in European and UK regulatory law related to pharmaceuticals, biotech and medical technologies


Bristows has promoted Life Sciences Regulatory expert, Xisca Borrás to the partnership. This appointment further strengthens the growing Life Sciences Regulatory team, which added three associates to its ranks in 2021.

Dual-qualified in England & Wales and Spain, Xisca specialises in European and UK regulatory law related to pharmaceuticals, biotech and medical technologies. Xisca joined Bristows in 2018 and applies her extensive in-house pharma experience to bring a unique, commercial approach to her role as trusted adviser to clients such as Alnylam, Boehringer, GSK, Novartis, Regeneron, Smith & Nephew, Takeda, and Teva – assisting them with pan-European strategic planning, litigation and advocacy in both the Court of Justice of the European Union and the English courts.

Alex Denoon, who leads the Life Sciences Regulatory team, commented: “This is an extremely exciting and demanding time to be a regulatory lawyer as virtually all aspects of the current framework are undergoing significant change. Xisca is an exceptional talent and we are thrilled to welcome her to the partnership. On a personal level, I couldn’t be more delighted.”

Bristows Joint Managing Partner, Liz Cohen commented: “The strength of Bristows’ Life Sciences practice is unmatched at European level, and Xisca’s promotion is the latest demonstration of this.” She continued: “We have a dedicated team of regulatory experts advising on cutting-edge issues on a daily basis. Not many firms can say the same.”

Bristows is a leader in the life sciences and technology sectors, offering full-service legal support to renowned clients developing disruptive technologies and therapies. The regulatory team is frequently asked to help clients navigate complex and changing regulatory issues arising in areas such as biologics, orphan medicines, genomics and cell therapies.

With this announcement, Bristows now has 43 partners, 28% of whom are women. Xisca’s promotion reflects the firm’s commitment to gender diversity and is indicative of a strong pipeline of senior women progressing towards partnership.

Related Articles